Tuberculosis Therapeutics Market Report 2026

The tuberculosis therapeutics market size has grown strongly in recent years. It will grow from $2 billion in 2025 to $2.13 billion in 2026 at a compound annual growth rate (CAGR) of 6.3%. The growth in the historic period can be attributed to global tb disease burden, widespread use of first-line tb drugs, expansion of government tb control initiatives, availability of generic tb medications, international funding support for tb programs.

The tuberculosis therapeutics market size is expected to see strong growth in the next few years. It will grow to $2.7 billion in 2030 at a compound annual growth rate (CAGR) of 6.1%. The growth in the forecast period can be attributed to growing prevalence of multidrug-resistant tb, advancements in novel tb drug development, increasing global health funding, expansion of digital adherence technologies, rising focus on preventive tb treatment. Major trends in the forecast period include increasing development of drug-resistant tb therapies, rising adoption of combination treatment regimens, growing focus on shorter treatment durations, expansion of public health tb programs, improved patient adherence monitoring.

The increasing rates of co-infection with tuberculosis (TB) and human immunodeficiency virus (HIV) are expected to drive the growth of the tuberculosis therapeutics market in the coming years. TB-HIV co-infection refers to individuals simultaneously affected by both diseases, a combination that complicates diagnosis, treatment, and clinical outcomes due to immune suppression and the overlapping nature of the epidemics. The rise in co-infection cases is increasing demand for integrated therapeutic approaches that address TB infection in HIV-positive populations, thereby improving patient outcomes and reducing the overall disease burden. For example, in March 2024, the Centers for Disease Control and Prevention reported that the number of tuberculosis cases increased from 8,320 in 2022 to 9,615 in 2023, reflecting a rise of 1,295 cases. As a result, growing TB-HIV co-infection rates are contributing to the expansion of the tuberculosis therapeutics market.

Leading companies in the tuberculosis therapeutics market are concentrating on the development of advanced treatment options, such as combination therapies, to enhance treatment effectiveness, shorten therapy duration, and address the challenge of drug-resistant tuberculosis strains. Combination therapy involves the use of two or more drugs from different classes to treat a disease, with the aim of increasing efficacy, minimizing resistance, and improving patient outcomes. For instance, in July 2024, Johnson & Johnson, a U.S.-based pharmaceutical company, reached a major milestone in tuberculosis treatment with the approval of SIRTURO (bedaquiline) by both the U.S. Food and Drug Administration (FDA) and the European Commission. This drug represents the first tuberculosis-specific treatment developed in more than four decades and is designed to target multidrug-resistant tuberculosis (MDR-TB). Its novel mechanism of action inhibits the ATP synthase enzyme essential for energy production in TB bacteria, providing a targeted therapeutic approach. When included in combination regimens, SIRTURO enhances overall treatment efficacy, reduces treatment duration, and improves patient adherence.

In May 2024, BioVersys AG, a Switzerland-based biotechnology company, entered into a strategic partnership with GSK plc to accelerate the clinical development of alpibectir (BVL-GSK098) for the treatment of tuberculosis. Through this collaboration, BioVersys and GSK aim to advance alpibectir through clinical development to address unmet needs in TB care. GSK plc is a U.K.-based pharmaceutical company focused on the development and manufacturing of innovative medicines, including therapies for tuberculosis.

Major companies operating in the tuberculosis therapeutics market are Pfizer Inc, Johnson & Johnson, Roche Holding AG, Merck & Co. Inc, Sanofi S.A, Novartis AG, GlaxoSmithKline plc, Viatris Inc, Cipla Limited, Lupin Limited, Alkem Laboratories Limited, Emcure Pharmaceuticals Limited, Sequella Inc, AstraZeneca plc, Eli Lilly and Company, Biofabri S L, LegoChem Biosciences, BioVersys AG, SENTAN Pharma Inc, ViChem Pharmaceuticals Inc, PDS Biotechnology Corporation, BioNTech SE, Qurient Co Ltd.

North America was the largest region in the tuberculosis therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tuberculosis therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the tuberculosis therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the tuberculosis therapeutics market by increasing costs of imported active pharmaceutical ingredients, formulation chemicals, packaging materials, and manufacturing equipment used in tb drug production. High-burden regions such as Asia-Pacific and Africa are particularly affected due to dependence on imported pharmaceutical inputs. These tariffs are raising drug prices and pressuring public healthcare budgets. However, they are also promoting domestic drug manufacturing, strengthening local pharmaceutical supply chains, and encouraging technology transfer for affordable tb drug production.

The tuberculosis therapeutics market research report is one of a series of new reports that provides tuberculosis therapeutics market statistics, including tuberculosis therapeutics industry global market size, regional shares, competitors with a tuberculosis therapeutics market share, detailed tuberculosis therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the tuberculosis therapeutics industry. This tuberculosis therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Tuberculosis therapeutics encompass pharmaceutical treatments developed to prevent and treat tuberculosis (TB), a bacterial infection caused by Mycobacterium tuberculosis. The aim of these therapeutics is to eliminate the bacteria, limit transmission, and enhance patient outcomes, particularly in cases involving drug-resistant strains.

The primary types of tuberculosis therapeutics include active tuberculosis (TB) and latent tuberculosis (TB). Active tuberculosis is a contagious bacterial disease caused by Mycobacterium tuberculosis that mainly affects the lungs and presents with symptoms such as a persistent cough, fever, and weight loss. Various product types are available, including isoniazid, rifampin, pyrazinamide, hydrazine derivatives, miscellaneous anti-tubercular drugs, and ethambutol. These therapeutics are administered through routes such as oral, parenteral, and others, and are distributed via channels including hospital pharmacies, retail pharmacies, and online pharmacies. They are used by a range of end users, including hospitals, clinics, ambulatory surgical centers, and others.

The tuberculosis therapeutics market consists of sales of combination therapies, vaccines, supportive therapies, biologics, and newer drugs. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.